Peter Maple

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5045413/publications.pdf

Version: 2024-02-01

33	953	516215 16	433756 31
papers	citations	h-index	g-index

33	33	33	1272
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Maternal HIV Infection and Placental Malaria Reduce Transplacental Antibody Transfer and Tetanus Antibody Levels in Newborns in Kenya. Journal of Infectious Diseases, 2007, 196, 550-557.	1.9	134
2	The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and Infection, 2005, 133, 159-171.	1.0	122
3	The sero-epidemiology of diphtheria in Western Europe. Epidemiology and Infection, 2000, 125, 113-125.	1.0	109
4	European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine, 2003, 22, 112-120.	1.7	88
5	Performance of a Time-Resolved Fluorescence Immunoassay for Measuring Varicella-Zoster Virus Immunoglobulin G Levels in Adults and Comparison with Commercial Enzyme Immunoassays and Merck Glycoprotein Enzyme Immunoassay. Vaccine Journal, 2006, 13, 214-218.	3.2	48
6	Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. Journal of Infection, 2010, 61, 73-80.	1.7	40
7	Sero-epidemiology of Bordetella pertussis in England and Wales. Vaccine, 2004, 22, 1314-1319.	1.7	38
8	Prevalence of Anti-Varicella-Zoster Virus Antibodies in French Infants under 15 Months of Age. Vaccine Journal, 2009, 16, 484-487.	3.2	38
9	Identification of Past and Recent Parvovirus B19 Infection in Immunocompetent Individuals by Quantitative PCR and Enzyme Immunoassays: a Dual-Laboratory Study. Journal of Clinical Microbiology, 2014, 52, 947-956.	1.8	38
10	Characterization of Treponema pallidum Particle Agglutination Assay-Negative Sera following Screening by Treponemal Total Antibody Enzyme Immunoassays. Vaccine Journal, 2010, 17, 1718-1722.	3.2	25
11	Comparison of fifteen commercial assays for detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals. Journal of Virological Methods, 2009, 155, 143-149.	1.0	24
12	Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection. Journal of Virological Methods, 2009, 157, 90-92.	1.0	23
13	Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. Journal of Clinical Virology, 2009, 44, 9-14.	1.6	20
14	Measurement of IgG antibodies to Chlamydia trachomatis by commercial enzyme immunoassays and immunofluorescence in sera from pregnant women and patients with infertility, pelvic inflammatory disease, ectopic pregnancy, and laboratory diagnosed Chlamydia psittaci/Chlamydia pneumoniae infection. Journal of Clinical Pathology, 2003, 56, 225-229.	1.0	19
15	Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers. Journal of Virological Methods, 2011, 172, 60-65.	1.0	19
16	Comparison of a commercial Varicella Zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and post vOka vaccination sera from healthcare workers. Journal of Clinical Virology, 2012, 53, 201-207.	1.6	16
17	Testing <scp>UK</scp> blood donors for exposure to human parvovirus 4 using a timeâ€resolved fluorescence immunoassay to screen sera and <scp>W</scp>estern blot to confirm reactive samples. Transfusion, 2013, 53, 2575-2584.	0.8	16
18	Is it appropriate to use fixed assay cut-offs for estimating seroprevalence?. Epidemiology and Infection, 2016, 144, 887-895.	1.0	16

#	Article	IF	Citations
19	A different response to cytomegalovirus (CMV) and Epsteinâ€“Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls. Journal of Infection, 2020, 80, 320-325.	1.7	16
20	Cytomegalovirus and Epsteinâ€“Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development. Vaccines, 2020, 8, 35.	2.1	13
21	Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England. Vaccine, 2014, 32, 1213-1217.	1.7	12
22	Viral load and antibody boosting following herpes zoster diagnosis. Journal of Clinical Virology, 2018, 103, 12-15.	1.6	12
23	Application of a noninvasive oral fluid test for detection of treponemal IgG in a predominantly HIV-infected population. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 743-749.	1.3	10
24	Varicella zoster immune status in children treated for acute leukemia. Pediatric Blood and Cancer, 2014, 61, 2077-2079.	0.8	10
25	An oral fluid test for syphilis. International Journal of STD and AIDS, 2005, 16, 299-301.	0.5	8
26	Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs. Vaccines, 2015, 3, 988-1003.	2.1	8
27	How Useful is COVID-19 Antibody Testing â€“ A Current Assessment for Oncologists. Clinical Oncology, 2021, 33, e73-e81.	0.6	8
28	Follow-up of pregnant women exposed to chicken pox: an audit of relationship between level of antibody and development of chicken pox. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 1193-1200.	1.3	7
29	The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay. Epidemiology and Infection, 2016, 144, 2345-2353.	1.0	7
30	Population (Antibody) Testing for COVID-19â€”Technical Challenges, Application and Relevance, an English Perspective. Vaccines, 2021, 9, 550.	2.1	6
31	An Absence of Epsteinâ€“Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines, 2020, 8, 487.	2.1	2
32	Multiple Sclerosis, Viruses, and New Vaccines. Neurology International, 2021, 13, 712-714.	1.3	1
33	Herpesvirus Vaccines. Vaccines, 2022, 10, 628.	2.1	0